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InﬂammationThe ErbB4 receptor has an important function in fetal lung maturation. Deletion of ErbB4 leads to alveolar
hypoplasia and hyperreactive airways similar to the changes in bronchopulmonary dysplasia (BPD). BPD is a
chronic pulmonary disorder affecting premature infants as a consequence of lung immaturity, lung damage,
and abnormal repair. We hypothesized that proper ErbB4 function is needed for the timely progression of
fetal lung development. An ErbB4 transgenic cardiac rescue mouse model was used to study the effect of
ErbB4 deletion on fetal lung structure, surfactant protein (SP) expression, and synthesis, and inﬂammation.
Morphometric analyses revealed a delayed structural development with a signiﬁcant decrease in saccular
size at E18 and more pronounced changes at E17, keeping these lungs in the canalicular stage. SP-B mRNA
expression was signiﬁcantly down regulated at E17 with a subsequent decrease in SP-B protein expression at
E18. SP-D protein expression was signiﬁcantly decreased at E18. Surfactant phospholipid synthesis was
signiﬁcantly decreased on both days, and secretion was down regulated at E18. We conclude that pulmonary
ErbB4 deletion results in a structural and functional delay in fetal lung development, indicating a crucial
regulatory role of ErbB4 in the timely progression of fetal lung development.DCt, Difference in threshold
nic day; SP, Surfactant protein;
; HER4heart+/−, Heterozygote
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ErbB receptors play important roles in fetal development [1–4].
ErbB receptors are expressed in fetal lung cells [5] and regulate fetal
lung maturation via mesenchyme–epithelial cell communication
[6,7]. Their expression in the fetal lung is regulated by a variety of
hormones and growth factors [8–10]. The growth factor neuregulin-1,
a ligand of ErbB3 and ErbB4 receptors, is secreted by the mature fetal
lung ﬁbroblast to stimulate the synthesis of surfactant by lung type II
epithelial cells [7]. In the fetal lung, ErbB4 is the most prominent ErbB
receptor dimerization partner [5,11]. Silencing of ErbB4 function
using siRNA inhibits fetal surfactant synthesis [12]. ErbB4 knockout
mice die at about E11 due to cardiac defects [2]. As in utero death
coincides with the onset of lung organogenesis, the role of ErbB
receptors in late fetal lung development and maturation needs to beelucidated. HER4heart transgenic mice are rescued from their lethal
cardiac defects by expressing the human ErbB4 cDNA under the
control of the cardiac-speciﬁc myosin (α-MHC) promoter. These
animals survive fetal development, can reach adulthood, and are
fertile. Adult survivors of homozygote (−/−) HER4heart transgenic
mice exhibit neural and mammary gland defects [13]. Their lungs
show alveolar simpliﬁcation, airway hyperreactivity, and signs of
chronic inﬂammation [14]. These defects might originate from
defective fetal development. Here we present the effects of ErbB4
deletion on late fetal lung development.2. Materials and methods
2.1. Materials
Rabbit anti-human surfactant protein (SP)-A, rabbit anti-sheep
SP-B, rabbit anti-human pro-SP-C, and rabbit anti-mouse SP-D
antibodies were from Chemicon Europe (Hofheim, Germany);
rabbit polyclonal ErbB4 (C-18) antibody was from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA); mouse monoclonal anti-actin
clone AC-40 was from Sigma (Hamburg, Germany); goat anti-
rabbit IgG (HRP-labelled) and goat anti-mouse IgG (HRP-labelled)
were from Zymed Laboratories Inc. (South San Francisco, CA);
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Rad Laboratories (Munich, Germany); protran nitrocellulose
transfer membrane was from Schleicher & Schuell BioScience
(Dassel, Germany); Western Lightning Chemiluminescence
Reagent Plus (enhanced chemiluminescence, ECL) and methyl
[3H]-choline chloride (speciﬁc activity 86 Ci/mol) were from
Perkin Elmer/Life Sciences (Boston, MA).2.2. HER4heart animals
HER4heart transgenic mice were kindly provided by Carmen
Birchmeier in agreement with Martin Gassmann. Animals were
housed in the animal facilities of Hannover Medical School and
Tufts University under pathogen-free conditions. The animal proto-
cols were approved by the institutional IACUC authorities at both
institutions. Animal experiments were performed using fetal E17, and
E18 HER4heart mice from heterozygote breedings. Genotyping was
performed as previously described [14].2.3. Fibroblast preparation
Pregnant mice were anesthetized, fetuses removed by C-section,
and kept in PBS on ice. The E17 fetal lungs were removed, pooled
according to genotype+/+ and−/−, minced into 1 mm3 pieces and
dissociated in Hanks buffered saline solution (HBSS) containing
DNase (20 µg/ml) and 0.25% trypsin at 37 °C for 10 min. The
dissociation was stopped by adding DMEM with 10% fetal calf
serum (FCS). The cells were ﬁltered through a sterile 45-μm cell
strainer and centrifuged at 650×g for 10 min at 4 °C. The cell pellets
were resuspended in DMEM with 10% FCS and cells were plated at
6×106/dish in 100 mm2 culture dishes for 60 min at 37 °C to allow for
lung ﬁbroblast adherence. The non-adherence cells were washed
away. The ﬁbroblasts were cultured until conﬂuence and analyzed for
ErbB4 receptor expression.2.4. Tissue processing
Fetal lungs were obtained and similarly divided into 3 pieces. One
part was ﬁxed in 4%PFA, 0.1% GA in 0.2 M HEPES buffer, pH 7.35 for
2 h, washed with 0.2 M HEPES buffer 6 times for 10 min, incubated in
sucrose solution overnight at 4 °C, and frozen for morphometric and
immunohistochemical analyses. The remaining two parts were snap-
frozen in liquid nitrogen, stored at −80 °C and used for protein and
RNA isolation. In additional experiments organotypic lung cultures
were prepared from individual fetuses, grown on grids at the air liquid
interface and used to study surfactant synthesis and secretion.2.5. Stereological analysis
Stereological analyses were carried out on a Nikon Eclipse 80i
microscope (Tokyo, Japan) using the Stereo Investigator Version 6
software (MicroBrightField Inc., Vermont, USA). Three serial hema-
toxylin–eosin stained cryostat sections (thickness 6 µm, interval
40 µm) from each animal were analyzed using a grid of test points
and cycloid lines. Morphometric parameters, including the surface
density and volume density of the saccules and their septae, the
arithmetic barrier thickness of septae, and the size of the saccules
were calculated in E18 lungs. In E17 lungs, the thickness and the
volume density of the septal tissue, the volume density of the airspace,
the surface density of the saccules or the canalicules, and the size of
the saccules or the canalicules were also calculated. This was
performed according to the point and intersection counting method
[15,16] as previously described [14].2.6. Western blot of surfactant protein expression
Western blot analyses of frozen fetal lungs for SP-A, SP-B, SP-C, and
SP-D expression were performed as described previously [14]. Protein
expression was quantiﬁed by densitometric evaluations for all
experiments.
2.7. Immunohistochemistry of surfactant proteins
Immunohistochemistry of lung cryosections for SP-A, SP-B, SP-C,
and SP-D was performed as described previously [17], with minor
modiﬁcations. Brieﬂy, 6-µm-thick sections were blocked with 3%
H2O2/PBS-solution and 5% goat serum, incubated for 15 min in an
Avidin/Biotin Blocking Kit (SP-2001, Vector Laboratories, Burlingame,
USA), and stained with rabbit anti-human surfactant protein (SP)-A,
rabbit anti-sheep SP-B, rabbit anti-human pro-SP-C, and rabbit anti-
mouse SP-D antibodies (Chemicon Europe, Hofheim, Germany)
overnight at 4 °C. Staining with the biotin-conjugated afﬁnity puriﬁed
goat anti-rabbit IgG (Chemicon International Inc. Europe, Hampshire,
UK) was followed by incubation in peroxidase-conjugated streptavi-
din (Jackson ImmunoResearch Europe Ltd., Newmarket, Suffolk, UK)
for 30 min. Then sections were incubated in DAB (diaminobenzidine)
solution for 10 min, rinsed in PBS/Tween, dehydrated in ascending
series of ethanol, and mounted in Entellan (Entellan Neu, Merck
KGaA, Darmstadt, Germany).
2.8. Surfactant protein mRNA expression
Real-time PCR for SP-A, SP-B, SP-C, and SP-DmRNAwas performed
as previously described [14]. Actin was used as an internal control to
normalize the surfactant protein cDNA levels. The relative expression
of SP mRNA was calculated using the Ct method. The amount of SP
mRNA relative to actin was expressed as 2−ΔCt. Relative SP mRNA
expression of HER4heart−/− animals was compared to the mRNA
expression of their litter-speciﬁc HER4heart+/− control animals and
presented as % of the control values.
2.9. Surfactant lipid synthesis (3H-choline incorporation and secretion)
Fetal lung organotypic cultures were prepared from individual
fetuses as previously described [18], cultured in DMEMwith 10% fetal
bovine serum for 48 h, and treated with 0.5 µCi/ml 3H-choline for the
following 24 h. The media of the cultures were collected for surfactant
lipid secretion analysis. The culture tissue was homogenized and
sonicated in ice cold PBS for surfactant lipid incorporation analysis.
Aliquots in duplicate were used for protein determination. Following
lipid extraction with chloroform and methanol, disaturated phospha-
tidylcholine (DSPC) was isolated by osmium tetroxide, and separated
by thin-layer chromatography on silica gel H chromatography sheets
as previously published [7,12]. The resulting spots were scraped into
scintillation ﬂuid, counted in a beta scintillation counter, expressed as
disintegrations per minute per μg protein, and normalized as percent
of experiment-speciﬁc controls (HER4heart+/− littermate lungs).
2.10. Immunohistochemistry of inﬂammatory cells
Immunostaining with CD11b antibodies was performed in 6-µm-
thick cryosections as described previously [19]. The procedures and
reagents were similar to the immunostaining of surfactant proteins
with the exception that the primary antibody was rabbit anti-mouse
CD11b (IgG2b, Clone M1/70.15, MorphoSys AbD GmbH, Düsseldorf,
Germany; 1:100 in PBS/Tween) antibody. Two to three serial staining
sections (interval 40 µm) were evaluated using a light microscope
(Nikon Eclipse 80i ﬂuorescence microscope, Nikon GMBH Duessel-
dorf, Germany). For each section, 300–400 test ﬁelds (size of the test
frame: 100×100 µm) were evaluated with a constant interval of
Table 1
Morphometric parameters in the lungs of E18 HER4heart−/− mice compared with
control HER4heart+/− mice.
Morphometric parameters % of litter-speciﬁc control p value
Volume density of parenchyma 100.44±0.39 0.35
Volume density of non parenchyma 92.85±8.84 0.22
Thickness of saccular septa 94.39±2.6 0.10
834 W. Liu et al. / Biochimica et Biophysica Acta 1803 (2010) 832–839400 µm between the test ﬁelds in both the x- and y-axes using a stereo
investigator system (MicroBrightField, Inc. Williston, Vermont, USA).
Cell densities of neutrophils and macrophages were evaluated after
counting the CD11b positive cells in the lung parenchyma and were
expressed as cell number per mm2 (cell density) using the following
formula:
Q =mm2 =
number × grid size 400 × 400 μmð Þ= test frame 100 × 100 μmð Þ × 1;000;000
area of interest
ðQ = = number of counted cellsÞ
2.11. Statistics
Data are presented as mean values±SEM, if not indicated
otherwise. N indicates the number of fetal lungs studied. Statistical
signiﬁcance was considered for p-values b0.05 using the Student's t-
test for those data following a normal distribution, and the Mann–
Whitney U test otherwise.
3. Results
3.1. ErbB4 expression
We conﬁrmed that E17 HER4heart−/− ﬁbroblasts did not express
ErbB4 receptor, while ErbB4 was expressed in HER4heart+/+ ﬁbro-
blasts (Fig. 1). The lack of ErbB4 expression in the HER4heart−/−
ﬁbroblasts is in agreement with the report of Tidcombe et al. who
found in this model that ErbB4 mRNA is expressed only in heart but
not in other organs such as brain, liver and mammary gland [13]. We
have previously reported that ErbB4 is normally expressed in late
gestation wild type fetal rat ﬁbroblasts and type II cells and in fetal
mouse type II cells and the mouseMLE12 type II cell line [5,10,11]. We
have also found that ErbB4 immunostaining is present in ﬁbroblast
clusters neighboring developing saccules and in occasional clusters of
columnar airway epithelium of late gestation mouse lungs (unpub-
lished data).
3.2. Lung morphology
Morphometric analyses of E18 lungs showed a signiﬁcant decrease
in the size of saccules to 91.78±2.92% (p=0.04) in fetal HER4heart−/−
lungs (N=13) compared to the lungs of their control HER4heart+/−
littermates (N=12) (Table 1). More dramatic changes were observed
at E17 in the lung structure of transgenic mice (Table 2). Most
HER4heart−/− lungs corresponded to the canalicular stage of lung
development at E17, whereas control lungs had appropriately
progressed to the saccular stage (Fig. 2A–D). These changes in the
HER4heart−/− lungs were conﬁrmed quantitatively. The thickness and
the visual volume density of the septal tissue were signiﬁcantly
increased (122.74±6.58%, p=0.016 and 122.23±3.5%, pb0.001
respectively), while the volume density of the airspace (73.71±
3.92%, pb0.001), and the size of the saccules and canalicules (71.77±
3.7%, pb0.001) were signiﬁcantly decreased in HER4heart−/− lungs
(N=9) compared to their HER4heart+/− littermate controls (N=6)
(Table 2). These results suggested that deletion of ErbB4 simpliﬁesFig. 1. Representative Western blot of ErbB4 expression in freshly isolated primary E17
ﬁbroblasts of HER4heart+/+ (left panel) and HER4heart−/− (right panel) lungs,
conﬁrming the deletion of ErbB4 in HER4heart−/− lungs.lung structure and delays alveolar development in the late fetal
period.3.3. Surfactant protein and mRNA expression
The expression of all four surfactant proteins was analyzed by
Western blot and by quantitative real time PCR. At E17, SP-A protein
was not changed (133±24%, N=7, p=0.2) and SP-A mRNA level
was signiﬁcantly decreased (50±5%, N=7, p=0.03) in HER4heart−/−
lungs compared toHER4heart+/− control lungs (100±3%,N=5; 100±
22%,N=5, respectively) (Fig. 3A). At E18, SP-A protein expressionwas
not changed (111±4%, N=11, p=0.15), but SP-A mRNA was
signiﬁcantly increased (141±16%, N=10, p=0.03) compared to
HER4heart+/− control lungs (100±6%, N=11; 100±11%, N=12,
respectively) (Fig. 3B). SP-B proteinwas not changed (90±7%,N=12,
p=0.2), but SP-B mRNA was signiﬁcantly decreased (64±7%, N=9,
p=0.04) at E17 in HER4heart−/− lungs compared to HER4heart+/−
control lungs (100±4%, N=8; 100±13%, N=4, respectively)
(Fig. 3C). At E18, SP-B protein was signiﬁcantly decreased (76±7%,
N=15, p=0.02), but SP-BmRNAwasnownormal (158±46%,N=14,
p=0.3) when compared to HER4heart+/− control lungs (100±7%,
N=13; 100±26%, N=14, respectively) (Fig. 3D). SP-C was not
changed at either the protein (101±9%, N=12, p=0.9) or mRNA
level (75±18%, N=10, p=0.4) at E17 in HER4heart−/− lungs
compared to HER4heart+/− control lungs (100±2%, N=8; 100±
38%,N=6, respectively) (Fig. 3E). At E18 SP-Cwas lower at the protein
level (84±6%, N=12, p=0.07) but higher at the mRNA level (122±
21%, N=13, p=0.6) compared to HER4heart+/− lungs (100±5%,
N=8; 100±18%, N=14 respectively) (Fig. 3F). However none of
these differences were signiﬁcant. Thus, SP-C was overall not affected
in fetal HER4heart−/− mice. At E17, both SP-D protein (173±62%,
N=7, p=0.3) and SP-D mRNA (195±64%, N=8, p=0.3) appeared
elevated in HER4heart−/− lungs compared to HER4heart+/− control
lungs (100±6%, N=5; 100±33%, N=6, respectively). However,
these increases did not reach statistical signiﬁcance (Fig. 3G). At E18,
SP-D protein was signiﬁcantly decreased (78±6%, N=15, p=0.014),
but SP-D mRNA was not changed (111±23%, N=13, p=0.2)
compared to HER4heart+/− control lungs (100±6%, N=13; 100±
16%, N=12, respectively) (Fig. 3H).3.4. Immunohiostochemestry of surfactant proteins
Immunohistochemistry for SP-A, SP-B, SP-C, and SP-D did not
show signiﬁcant differences in the location of surfactant protein
expression (data not shown). Staining for SP-B was detected in Clara
cells and in developing type II cells of E18 HER4heart+/− (A) and
HER4heart−/− (B) fetal lungs (Fig. 4).Volume density of saccular septa 98.46±2.42 0.76
Volume density of saccular space 95.73±3.02 0.46
Surface density of saccules 105.01±2.83 0.23
Size of alveolar saccules 91.78±2.92 0.04⁎
Volume density of ductal space 104.39±6.0 0.70
Size of alveolar ducts 95.18±3.83 0.45
Volume density of ductal septa 108.51±4.67 0.17
Thickness of alveolar ductal septa 102.11±3.27 0.68
Data presented as mean (%)±SEM.
⁎ pb0.05.
Table 2
Morphometric parameters in the lungs of E17 HER4heart−/− mice compared with
control HER4heart+/− mice.
Morphometric parameters % of family speciﬁc control p value
Thickness of septal tissue 122.74±6.58 0.016⁎
Volume density of septal tissue 122.23±3.50 b0.001⁎
Volume density of airspace 73.71±3.92 b0.001⁎
Surface density saccules/canalicules 104.01±4.42 0.91
Size saccules/canalicules 71.77±3.70 b0.001⁎
Data presented as mean (%)±SEM.
⁎ pb0.05.
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3H-Choline incorporation into disaturated phosphatidylcholine
(DSPC), a measure of surfactant phospholipid synthesis, was
signiﬁcantly decreased to 64.7±7.6% (N=4) in E17 HER4heart−/−
lungs compared to HER4heart+/− lungs (N=9) (p=0.008) (Fig. 5A),
and to 50.9±11.5% (N=5) in E18 HER4heart−/− lungs compared to
HER4heart+/− lungs (N=14) (p=0.0012) (Fig. 5B). Surfactant
secretion, measured as 3H-labelled DSPC content in the culture
media, was signiﬁcantly decreased only in E18 HER4heart−/− lungs to
51.6±9.8% (N=5) compared to HER4heart+/− lungs (N=14)Fig. 2. Histological pictures of E17 control HER4heart+/− (A, C) and HER4heart−/− (B, D) lung
and eosin. HER4heart−/− (B) lungs have fewer transitory ducts and saccules compared to HER
the air spaces in control lungs (C). HER4heart−/− (D) lungs have less sacculi and show accum
increased volume density of the septal tissue and a decreased volume density of the airspa(p=0.011), (Fig. 5B). At E17 this did not reach statistical signiﬁcance
(HER4heart−/− lungs 65.4±23.6%, N=4 compare to HER4heart+/−
lungs 100±21.8%, N=9, p=0.36) (Fig. 5A).
In summary, deletion of ErbB4 disturbs pulmonary surfactant
homeostasis by down regulation of SP-B and SP-D expression and
surfactant phospholipid synthesis and secretion in the late gestation
lung.
3.6. Inﬂammatory cells in the lung
Immunohistochemistry for CD11b showed an increase in inﬂam-
matory cells in E17 and E18 HER4heart−/− lungs (Fig. 6A). Cell density
of CD11b positive cells was signiﬁcantly increased to 291.2±58.4
(p=0.005) and 47.1±7.6 (p=0.0017) cells/mm2 at E17 and E18,
respectively in HER4heart−/− lungs (N=7) compared to HER4heart+/−
controls (84.3±14.82 and 15.3±2.3 cells/mm2, respectively; N=7)
(Fig. 6B-a,b). This leads to the conclusion that deletion of ErbB4
interferes with the development of the innate pulmonary immune
system, triggering a chronic inﬂammatory response.
4. Discussion
Pulmonary deletion of ErbB4 resulted in an overall delay in the
timely progression of fetal lung development. Delayed structurals. Representative light microscopic images from cryosections stained with hematoxylin
4heart+/− control lungs (A). A higher resolution showsmore epithelial cells surrounding
ulation of tissue containing mesenchyme cells. Morphometric evaluations revealed an
ce in HER4heart−/− lungs.
Fig. 3. SP expression. SP-A, SP-B, SP-C, SP-C, and protein expression in E17 (A, C, E, G, respectively) and E18 (B, D, F, H, respectively) lungs. Representative Western blot from
HER4heart+/− (left) and HER4heart−/− (right) lung homogenates. Quantiﬁcation of protein (left) and mRNA (right) expression in lung homogenates from HER4heart+/− (white bars)
and HER4heart−/− (black bars) transgenic mice. Values are presented as mean±SEM, N=4, *: pb0.05.
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the stage when the lungs normally advance from the canalicular to
the saccular stage. Some catch-up in structural development was
observed, as there were less obvious changes in the anatomic
structure of the ErbB4-deleted lungs at E18. Since a degree of
alveolar simpliﬁcation persists in the adult HER4heart−/− lungs [14],
we speculate that the overall catch-up in progression of lung
morphogenesis is not completed at the end of structural lung
development in these animals. The murine fetal lung develops
morphologically in 4 distinct stages, the pseudoglandular (E9.5–
E16.5), the canalicular (E16.5–17.5), the saccular (E17.5–P5) and the
alveolar (P5-30) stage [20]. The short duration at the canalicularstage makes the murine model at this gestation very useful for
studying the effects of gene deletion on the progression of fetal lung
morphogenesis. A similar histological picture is present in fetal
mouse lungs lacking tumor necrosis factor-α converting enzyme
(TACE). TACE plays a central role in the cleavage and shedding of the
ErbB4 ectodomain [21]. Morphologically TACE-deleted animals have
immature lungs with decreased lung branching and increased
thickness of pulmonary mesenchyme [22], similar to the changes
in the ErbB4 deleted lungs, suggesting that the disruption of lung
development may be related to an inhibition of ErbB4 function in
these animals. Other knock out animal models are known for an
arrest in the maturation of the surfactant system at the canalicular
Fig. 4. Immunohistochemistry of SP-B protein expression in E18 control HER4heart+/− (A) and HER4heart−/− (B) fetal lungs. Representative images of lung sections from HER4heart−/
− lungs (B) compared with HER4heart+/− control lungs (A). Dark brown staining is seen in SP-B-positive cells which include type II epithelial (small arrows) and Clara cells (large
arrow head).
837W. Liu et al. / Biochimica et Biophysica Acta 1803 (2010) 832–839stage of lung development, e.g. in mice missing the gene for
parathyroid hormone-related protein (PTHrP). Fetal and newborn
PTHrP(−/−) lungs show delayed mesenchyme–epithelial interac-
tions leading to an arrested type II cell differentiation and a disrupted
development of the pulmonary surfactant system [23]. These
similarities in the phenotype in PTHrP and ErbB4 (−/−) lungs are
consistent with the observations that ErbB receptor signaling may
regulate PTHrP gene expression in various epithelial cells. For
example, the epidermal growth factor (EGF) receptor activates
PTHrP gene expression in human keratinocytes [24] and EGF
activates PTHrP gene expression in various types of epithelial cells
[25,26].
At E18, the structure of ErbB4-deleted fetal lungs showed evidence
of catch-up maturation with progression into the saccular stage. The
observation of this catch-up structural development in HER4heart−/−
lungs at E18 suggests the activation of compensatory mechanisms to
correct for the missing function of ErbB4. Those mechanisms might
include the participation of other ErbB receptors. The potential role of
compensatory signaling by the remaining ErbB receptors is much
more complex than a simple evaluation of receptor protein amounts.
Overall baseline expression of the remaining ErbB4 receptors appears
unchanged (work in progress), but distinct changes in dimer
formation, receptor phosphorylation patterns, speciﬁc signaling, and
receptor fate might be involved. ErbB2 is the ErbB receptor
predominantly involved in direct interactions with other proteins
[27–29], and would be a likely candidate for involvement in a
compensatory process. Other signaling pathways such as the PTHrPFig. 5. DSPC synthesis (left group) and secretion (right group) in E17 (A) and E18 (B) fet
transgenic mice. Values are presented as mean±SEM, N=4–14, *: pb0.05.pathway, known for its interaction with the EGFR [24–26] might also
be involved. Further detailed studies are needed to elucidate these
compensatory mechanisms.
Adult HER4heart−/− animals show signs of airway hyperreactivity
and an underlying chronic inﬂammation [14]. This inﬂammation may
have in part contributed to the pulmonary morphometric abnormal-
ities seen in those adult animals. In this study we found that the late
gestation fetal lungs already showed increased numbers of inﬂam-
matory cells. Based on this, we propose that there is an underlying
abnormality in regulation of development of the lung inﬂammatory
system in these ErbB4-deleted lungs.
Fetal ErbB4 deletion led to decreased surfactant phospholipid
synthesis and delayed SP-B expression. The normalization of SP-B
expression in the adult animals [14] is consistent with the observation
that homozygous negative animals can survive without postnatal
symptoms of surfactant deﬁciency and indicates a possible catch-up in
the development of the surfactant system in association with the
catch-up in morphologic development. In contrast to SP-B deﬁciency,
the persistent change of SP-D protein expression in adulthood [14]
may contribute to the increased numbers of inﬂammatory cells in the
fetal lung, demonstrating a role of SP-D in the developmental control
of lung immunity [30,31]. SP-D is a member of the collectin family
with immunoregulatory functions [32]. An increased number of
inﬂammatory cells in HER4heart−/− lungs is indicative of abnormal
regulation of pulmonary immune development in the ErbB4-deleted
lungs. In the fetal lung this led to an upregulation of SP-D mRNA, but
not the SP-D protein. This is an obvious disconnect between theal lung homogenates from HER4heart+/− (white bars) and HER4heart−/− (black bars)
Fig. 6. A: Representative immunohistochemical images of CD11b expression in E18 control HER4heart+/− (a) and HER4heart−/− (b) fetal lung sections. Arrows indicate CD11b-
positive cells, which are more frequently seen in HER4heart−/− lungs. B: Quantiﬁcation of cell density (cells/mm2) of CD11b positive cells in E17 (a) and E18 (b) fetal HER4heart−/−
lungs (black bars) compared with HER4heart+/− control lungs (white bars). Values are presented as mean±SEM, N=7, *: pb0.05.
838 W. Liu et al. / Biochimica et Biophysica Acta 1803 (2010) 832–839protein and RNA level. The upregulation of SP-D mRNA in the fetal
lung might be viewed as an attempt to appropriately regulate the
development of lung immunity. The reason that the increased SP-D
mRNA is not reﬂected in an increase in protein is not clear. It may
reﬂect a block in transcription or an increased turnover of the protein
in the fetal lungs. In adult HER4heart−/− animals, signs of chronic
inﬂammation persist, but SP-D protein and mRNA expression are
signiﬁcantly downregulated [14], suggesting a burn out phenomenon
of the RNA upregulation later in life.
Taken together, the ﬁndings of affected morphologic development
in these animals are similar to a BPD-like picture observed in
premature lambs after antenatal exposure to corticosteroids or
cytokines [33,34]. Prenatal inﬂammation is an important triggering
event in the pathogenesis of BPD [35], although the exact mechanisms
are unknown. In vitro experiments show that glucocorticoid treat-
ment promotes the maturation of the surfactant system [7] and
simultaneously changes the expression and dimerization pattern of
ErbB receptors in fetal type II cells from a prominent role of ErbB4
towards prominence of ErbB2 signaling [10]. Antenatal glucocorticoid
administration improves lung maturation and prevents RDS in
preterm infants [36], but the beneﬁts coincide with an inhibition of
alveolar development. The facts that glucocorticoids alter ErbB
signaling in fetal lungs and that the anatomic structural changes in
the glucocorticoid-treated lungs [33] are similar to those we have
identiﬁed in fetal and adult ErbB4-deleted lungs [14] suggest that
ErbB receptor dysregulation [10] might mediate some of the
glucocorticoid effects on developing lung morphogenesis. Reduced
branching and increased mesenchymal area around airspaces, as wellas disrupted surfactant composition and function in the lungs of
HER4heart−/−mice conﬁrms the important role of ErbB4 receptors for
the regulation of a timely progression of lung development. Our
results suggest that the ErbB4 receptor is critical for a timely transition
from the canalicular to saccular stage. This is not surprising since
ErbB4 is well known for its role in the timely onset of other
maturational processes including puberty [37] and the control of
astrogenesis [38]. A loss of ErbB4 function may partially be rescued by
compensatory mechanisms that likely include changes in the
expression, dimerization patterns and receptor phosphorylation of
the other three ErbB receptors. The fact that compensatory mechan-
isms exist suggests the basic importance of ErbB4 for normal lung
development, as evolutionary mechanisms have been developed to
compensate for its possible loss. This transgenic ErbB4 mouse model
might be useful in studying the pathogenesis and treatment of
neonatal lung disease.Acknowledgements
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